Enrollment ending soon for our study of daily versus long-acting antipsychotic medication
Please note that enrollment into our 12-month study comparing oral risperidone versus long-acting Invega Sustenna will be ending on June 30th. Both medications are FDA approved and are provided free of charge. Medication visits, psychologist visits, and group therapy are included. Participation in a separate protocol to increase thinking skills (i.e. attention, learning, and memory) is also available. To see if you, your family member, or someone you are treating is eligible, please call (310) 206-3142, or e-mail Joseph Ventura, PhD (email@example.com).
May is Mental Health Awareness Month
#WhyCare is part of NAMI’s initiatives to raise awareness on important topics regarding mental health. One in 5 Americans is affected by mental health conditions. Stigma is toxic to their mental health because it creates an environment of shame, fear and silence that prevents many people from seeking help and treatment. The perception of mental illness won’t change unless we act to change it.
WELCOME to the Aftercare Research Program at the UCLA Semel Institute
The Aftercare Research Program is an outpatient research clinic that provides assessment and treatment and conducts research with people who have recently experienced psychotic symptoms. The Program is designed to aid in the adjustment to life in the community. Our Program psychiatrists provide medication management, and our case managers provide education, psychotherapy, and cognitive training. Our staff also helps our participants in accomplishing goals such as returning to school and/or work.
Our team is comprised of a diverse group of professionals who have had extensive training in helping young adults who have recently become ill with a psychotic disorder. Our staff works as a team to provide the best possible care to our participants. We believe our Program’s strength lies in the comprehensive and individualized treatment we provide to our participants.